1. Home
  2. JBGS vs CRVS Comparison

JBGS vs CRVS Comparison

Compare JBGS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBG SMITH Properties

JBGS

JBG SMITH Properties

HOLD

Current Price

$12.29

Market Cap

823.7M

Sector

Real Estate

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

SELL

Current Price

$10.57

Market Cap

843.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JBGS
CRVS
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
823.7M
843.7M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
JBGS
CRVS
Price
$12.29
$10.57
Analyst Decision
Sell
Strong Buy
Analyst Count
3
7
Target Price
$12.00
★ $31.50
AVG Volume (30 Days)
779.9K
★ 1.0M
Earning Date
11-17-2026
11-05-2026
Dividend Yield
★ 5.97%
N/A
EPS Growth
N/A
★ 48.04
EPS
N/A
★ N/A
Revenue
★ $498,598,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.61
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$9.93
$6.39
52 Week High
$18.79
$26.95

Technical Indicators

Market Signals
Indicator
JBGS
CRVS
Relative Strength Index (RSI) 56.77 38.28
Support Level $10.83 $9.21
Resistance Level $12.77 $10.81
Average True Range (ATR) 0.38 0.56
MACD 0.11 0.08
Stochastic Oscillator 68.67 32.53

Price Performance

Historical Comparison
JBGS
CRVS

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: